HOME > COMMENTARY
COMMENTARY
- COMMENTARY/Major Wholesalers vs Hansha Competition to Intensify on Growing Market for Generics
March 3, 2008
- COMMENTARY/Preparations for New OTC Drug Marketing System Enter Final Stage
March 3, 2008
- COMMENTARY/Japan Needs to Create Attractive "Stadium for Drug Discovery" and Invite Top-Level Players
February 25, 2008
- COMMENTARY/Revision of Medical Fees May Increase Use of Drugs for Stroke, Mental Illnesses, Cancer
February 11, 2008
- Current New Drug Development in the Japanese Pharmaceutical Industry(2)
February 11, 2008
- Current New Drug Development in the Japanese Pharmaceutical Industry(1)
February 11, 2008
- COMMENTARY/Generic Makers Increase Investment, but Will Consumption Really Increase as Gov't Hopes?
February 4, 2008
- COMMENTARY/Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- OPINION/The East versus West Dilemma
January 28, 2008
- COMMENTARY/Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- No More Need for MRs? -A Hell beyond the 2010 Crisis?-
January 14, 2008
- COMMENTARY/Year 2007 in Retrospect
December 24, 2007
- COMMENTARY/Appreciation Mixed with Concern: Proposed NHI Pricing Reform
December 17, 2007
- COMMENTARY/Fight over Medical Fee/NHI Price Revision Rates Begin
December 3, 2007
- COMMENTARY:Korosho Must Explain Its "Primary Doctor" System Proposal in Detail
October 1, 2007
- Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
- COMENTARY:Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
- COMMENTARY/NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
- COMMENTARY/Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
- COMMENTARY/Market for Osteoporosis Drugs Booms
July 9, 2007
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…